Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry

Angelo Antonini, Werner Poewe, K. Ray Chaudhuri, Robert Jech, Barbara Pickut, Zvezdan Pirtošek, Jozsef Szasz, Francesc Valldeoriola, Christian Winkler, Lars Bergmann, Ashley Yegin, Koray Onuk, David Barch, Per Odin, Ene Amalia, Guy Arnold, Ovidiu Bajenaru, Bruno Bergmans, Kari Anne Bjornara, Jeff BlackieMatthias Bode, Paul Bourgeois, Stephan Bohlhalter, Ioan Buraga, Pierre R. Burkhard, Philippe Busson, Matilde Calopa, Jesper Clausen, Erik Hvid Danielsen, Luc Defebvre, Valerie Delvaux, Sophie Dethy, Espen Dietrichs, Oriol De Fabregues, Ransmayr Gerhard, Graziano Gusmaroli, Kirsten Hahn, Björn Hauptmann, Tove Henriksen, Jorge Hernandez-Vara, A. Jeanjean, Michaela Kaiserova, Jan Kassubek, Thomas Kimber, Spyridon Konitsiotis, Rejko Krüger, Jaime Kulisevsky, Jo Leenders, Christofer Lundqvist, Nicola Modugno, GLORIA study co-investigators

Research output: Contribution to journalArticlepeer-review


Introduction This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intestinal gel (LCIG) treatment in advanced Parkinson's disease (PD) patients under routine clinical care. Methods Motor fluctuations, dyskinesia, non-motor symptoms, quality of life, and safety were evaluated. Observations were fully prospective for treatment-naïve patients (60% of patients) and partially retrospective for patients with ≤12 months of pre-treatment with LCIG (40% of patients). Hours of “On” and “Off” time were assessed with a modified version of the Unified Parkinson's Disease Rating Scale part IV items 32 and 39. Results Overall, 375 patients were enrolled by 75 movement disorder centers in 18 countries and 258 patients completed the registry. At 24 months LCIG treatment led to significant reductions from baseline in “Off” time (hours/day) (mean ± SD = −4.1 ± 3.5, P < 0.001), “On” time with dyskinesia (hours/day) (−1.1 ± 4.8, P = 0.006), Non-Motor Symptom Scale total (−16.7 ± 43.2, P < 0.001) and individual domains scores, and Parkinson's Disease Questionnaire-8 item total score (−7.1 ± 21.0, P < 0.001). Adverse events deemed to have a possible/probable causal relationship to treatment drug/device were reported in 194 (54%) patients; the most frequently reported were decreased weight (6.7%), device related infections (5.9%), device dislocations (4.8%), device issues (4.8%), and polyneuropathy (4.5%). Conclusions LCIG treatment led to sustained improvements in motor fluctuations, non-motor symptoms particularly sleep/fatigue, mood/cognition and gastrointestinal domains, as well as quality of life in advanced PD patients over 24 months. Safety events were consistent with the established safety profile of LCIG.

Original languageEnglish
Pages (from-to)13-20
Number of pages8
JournalParkinsonism and Related Disorders
Publication statusPublished - Dec 1 2017


  • Levodopa-carbidopa intestinal gel
  • Motor symptoms
  • Non-motor symptoms
  • Parkinson's disease
  • Routine patient care

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology


Dive into the research topics of 'Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry'. Together they form a unique fingerprint.

Cite this